logo

For the Inventor, By the Inventor

Warrington, PA, United States of America

John Yelnosky

USPTO Granted Patents = 17

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 62(Granted Patents)


Company Filing History:

goldMedal14 out of 146 
 
William H. Rorer, Inc.
 patents
silverMedal3 out of 109 
 
Rorer Pharmaceutical Corporation
 patents

Years Active: 1980-1988

Loading Chart...
17 patents (USPTO):Explore Patents
1. 4745131 - Amidinoureas for treating irritable bowel syndrome (1988-05-17),
2. 4714707 - Aryl substituted heterocycles for treating gastrointestinal motility (1987-12-22),
3. 4701457 - Amidinoureas for treating irritable bowel syndrome (1987-10-20),
4. 4689335 - Heterocyclic guanidines for treating gastrointestinal motility (1987-08-25),
5. 4611011 - Amidinoureas for treating irritable bowel syndrome (1986-09-09),
6. 4563475 - Guanidine derivatives for treating gastrointestinal motility dysfunction (1986-01-07),
7. 4563460 - Quinoline and quinazoline derivatives for treating gastrointestinal (1986-01-07),
8. 4563456 - 1,2,4-Triazines for treating gastrointestinal motility dysfunction (1986-01-07),
9. 4562188 - Triazinones for treating irritable bowel syndrome (1985-12-31),
10. 4486439 - Treatment of coccidiosis (1984-12-04),
11. 4298608 - Method for blocking high frequency nerve stimulation (1981-11-03),
12. 4285972 - Method of treating scours (1981-08-25),
13. 4279928 - Method of lowering blood pressure (1981-07-21),
14. 4203985 - Antidiarrheal triazinones (1980-05-20),
15. 4203983 - Spasmolytic triazinones (1980-05-20),

Title: The Innovative Contributions of John Yelnosky

Introduction

John Yelnosky is a notable inventor based in Warrington, Pennsylvania, who has made significant contributions to the field of pharmaceuticals. With a total of 17 patents to his name, Yelnosky has focused on developing innovative treatments for gastrointestinal disorders, particularly irritable bowel syndrome.

Latest Patents

Among his latest patents, Yelnosky has developed amidinoureas for treating irritable bowel syndrome. The compound 1-Phenyl-3N-alkyl amidinoureas has shown promise in alleviating the symptoms associated with this condition. Additionally, he has worked on aryl substituted heterocycles for treating gastrointestinal motility dysfunctions. These aryl substituted diazaheterocyclic amines represent a significant advancement in the treatment of gastrointestinal motility issues.

Career Highlights

Throughout his career, Yelnosky has been associated with reputable companies such as William H. Rorer, Inc. and Rorer Pharmaceutical Corporation. His work in these organizations has allowed him to contribute to the development of effective pharmaceutical solutions.

Collaborations

Yelnosky has collaborated with esteemed colleagues, including William L. Studt and Donald E. Kuhla. These partnerships have further enhanced his research and development efforts in the pharmaceutical industry.

Conclusion

John Yelnosky's innovative work in the field of pharmaceuticals has led to significant advancements in the treatment of gastrointestinal disorders. His contributions continue to impact the lives of many individuals suffering from these conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…